In recent years, immune checkpoint inhibitors, especially PD-1 and its ligand PD-L1 inhibitors, have been widely concerned because of their universality, significant anti-tumor activity and good safety, which improve the prognosis of patients with advanced non-small cell lung cancer. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.